Search PubMed⌕ Search

Biomedical subjects

J Sakatoku

Publications and source records attributed to J Sakatoku.

At least 37 records · Page 2Linked to original sources
PubMed1990

[Utility of pre-operative imaging diagnosis in spermatic cord liposarcoma].

A case of spermatic cord liposarcoma was revealed by imaging diagnosis. The patient was a 59-year-old male, who consulted our clinic with the complaint of painless right scrotal swelling on June 30, 1989. One year earlier, he noticed this swelling, which was slow growing little by little. Palpation revealed a movable mass in right scrotum, 7 x 3 x 3 cm in size and separated from the right testis. Scintigraphy could not show RI accumulation and ultrasonography showed a capsulated homogeneous mass. Computed tomography (CT) and magnetic resonance imaging (MRI) showed capsulated fat-like almost homogeneous mass, which enclosed the right spermatic cord. This mass was suspected of spermatic cord lipoma or liposarcoma and was removed with radical orchiectomy. The weight of the mass was 246 g. This mass had a bunch of grape appearance and consisted of several masses of various sizes surrounding the spermatic cord, and could be separated from the right epididymis and testis. Histological examination revealed well differentiated liposarcoma and lipoma. Spermatic cord liposarcoma is very rare and this preoperative diagnosis is very difficult. Imaging diagnosis, such as CT, MRI may help our preoperative diagnosis.

Genital Neoplasms, Male↗
PubMed1990

[Subrenal capsule assay for chemosensitivity test of urological malignancy].

We evaluated the subrenal capsule assay with a chemosensitivity test using 47 fresh surgical explants, including 16 renal cell carcinomas and 10 uroepithelial cancers. Forty-one explants were evaluable and 166 drug tests were performed. Forty-seven tests (28.3%) were found to be sensitive. Ten of 16 renal cell carcinomas involved a sensitive drug, 3 involved more than 2 sensitive drugs. VP-16, ADM, BLM and 5-FU were the most sensitive compared with the others. Concerning the uroepithelial cancers, 8 of 10 involved a sensitive drug, 5 involved more than 2 sensitive drugs. CDDP and VP-16 were more effective than the other drugs. This result showed a good correlation with the clinical therapeutic efficacy using CDDP. In the future, we hope to evaluate the clinical correlation between clinical efficacy and this assay.

Adenocarcinoma↗
PubMed1989

[Study of flow cytometric BrdU/DNA assay].

To investigate the possibility of flow cytometric BrdU/DNA assay as a rapid chemosensitivity test, preliminary studies were performed utilizing CDDP-sensitive and CDDP-resistant mouse leukemic L1210 cell lines. The results indicated that the anticancer effects of CDDP to these cells could be rapidly determined by analyzing the effects on cell kinetics and the effects on BrdU uptake with this method. Also, this method could detect CDDP-resistant cells at proportion approaching 0.1% in a predominantly CDDP-sensitive population. In the near future, this flow cytometric method could be utilized not only as a useful screening test for anticancer drugs for initial cancer chemotherapy but also as a monitoring test to rapidly detect drug-resistant cells and thereby aid in the selection of a more effective anticancer therapy.

Animals↗
PubMed1989

The application of intrascrotal deep body temperature measurement for the noninvasive diagnosis of varicoceles.

The authors used intrascrotal deep body (intratesticular) temperature measurement in an attempt to make the diagnosis of varicoceles more objective. Two hundred five male patients complaining of infertility were classified into three groups: group A consisted of 84 patients with varicocele; group B of 66 patients without varicocele; and group C of 55 patients after varicocelectomy. The bilateral intrascrotal temperatures were recorded in the supine position and then monitored continuously in the standing position. The maximum temperatures in both positions were compared between each group. The mean temperature of the varicocele group was higher than that of the other two groups in the standing position. The authors studied the difference in temperature (delta T) due to postural change from supine to standing. The mean delta T of the left testis was +0.78 degrees C in the varicocele group, whereas it was approximately -0.5 degrees C in the other two groups. The authors conclude that deep body temperature provides a practical index of the intrascrotal temperature and is useful as one of the objective, clinical criteria for the diagnosis of varicocele.

Body Temperature↗
PubMed1989

[Prostate-specific antigen (PA) and deoxyribonucleic acid (DNA) analysis in prostatic epithelial cells using flow cytometry].

We developed a new method to analyze simultaneously cellular prostate-specific antigen (PA) content and deoxyribonucleic acid (DNA) content of each prostatic epithelial cell by using flow cytometry (FCM). We report the possibilities of this method and we analyzed firstly 8 samples from 6 patients with benign prostatic hypertrophy (BPH). The content of cellular PA and DNA of prostatic epithelial cells can be analyzed simultaneously. The PA is synthesized only in the cells with a 2C DNA content (G0/1 cells) and not in the S- or G2M-phase cells. In the near future, by applying this analytical method to prostatic cancer samples we could obtain more interesting knowledge of the behavior of prostatic cancer.

Aged↗
PubMed1989

[Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].

Serum prostatic specific antigen (PA), gamma-seminoprotein (gamma-Sm) and prostatic acid phosphatase (PAP) levels were measured in 113 untreated patients with prostatic cancer and in 137 patients with benign prostatic hypertrophy (BPH). We used a PA-TESTWAKO enzyme immunoassay kit, gamma-Sm enzyme immunoassay kit and PAP radioimmunoassay kit. Of the 113 patients, 81.4%, 73.5% and 69%, respectively, were detectable using a single assay. PA was more sensitive than the other two markers in all stages, especially in localized disease (stages A, B and C). Using the BPH group as a negative control, specificities of PA, gamma-Sm and PAP were 85.4%, 81.0% and 94.2%, respectively. Efficiency was, respectively, 81.2%, 79.6% and 82.8%. In the follow up period, 15 patients presented disease progression. At the time of clinical detectable progression, the sensitivities of PA and gamma-Sm were both 100% (15/15), while 67% (10/15) for PAP. Concerning the sensitivity within 6 months prior to progression, gamma-Sm and PA tended to be more sensitive than PAP in early detection of disease progression. This study shows that PA is more reliable than gamma-Sm and PAP in detecting and staging of prostatic cancer. gamma-Sm and PA appear to be more reliable in earlier prediction of disease progression.

Acid Phosphatase↗
PubMed1989

[Study of flow cytometric bromodeoxyuridine (BrdU)/DNA analysis using human solid tumors].

In spite of the development of a staining principle and the method for simultaneous flow cytometric bromodeoxyuridine (BrdU)/DNA analysis, this technic was seldom used clinically, because, it can not be applied for the study of solid tumors. In this paper, we described a new method to overcome this problem by combining proteolytic enzyme digestion with previously reported immunofluorescent procedure. The difficulty of two-color analysis in solid tumors using previously reported method came from the non-specific staining of resulted cells which have Fc receptors on each cell surface and hence the gaps between S- and G1- or G2M-phase were unclear. By combining proteolytic enzyme digestion, the normal cell population can be excluded easily and the gaps between these phases be clearly distinguished, therefore the results obtained by this new method seemed to be more precise. This new method can be applied for solid tumor studies and the development for clinical application is expected.

Animals↗
PubMed1989

[Flow cytometric bromodeoxyuridine (BrdU)/DNA analysis--study with urogenital tumors].

We performed the simultaneous flow cytometric bromodeoxyuridine (BrdU)/DNA analysis in combination with in vitro BrdU labeling method using seven human urogenital tumors. The DNA content and incorporated BrdU content of each tumor cell was analyzed quantitatively using this flow cytometric method. The cell kinetics of each cell line of heterogeneous tumor could be analyzed by this combined method. In the near future, by establishing a procedure decreasing non-specific staining of cells, the development of this flow cytometric two-color analysis in clinical fields is expected.

Aged↗
PubMed1989

[Cell kinetic study of urogenital tumors utilizing in vitro BrdU-labelling method and anti-BrdU monoclonal antibody].

With the aim to apply a rapid analytic method of cell kinetics using in vitro BrdU labelling and anti-BrdU monoclonal antibody to the clinical fields, we investigated the cell kinetics of 20 urogenital malignant tumors. The DNA synthesizing cells which take up BrdU in its nuclei can be detected so clearly, since the labelling index (LI) is easily identified. The correlations between LI and age and with histological grade and stage of 14 transitional cell cancers of urinary tract were investigated. There was no correlation between LI and age. The LI of high grade groups (G2 & G3) were significantly higher than that of the low grade group (G1) (p less than 0.05). Also between LI of pT1 group and pT3 group, there was a statistical significance (p less than 0.05) and generally LI tended to increase according to stage progression. Therefore, the cytokinetic data obtained from the before mentioned method can be utilized as a useful marker for measuring malignant potentials of each tumor.

Aged↗
PubMed1987

Significance of testicular size measurement in andrology: II. Correlation of testicular size with testicular function.

The testicular sizes of 305 men were measured by a recently developed orchidometer and related to 9 other known parameters of testicular function. Mean testicular size had the strongest correlation with serum follicle-stimulating hormone levels, total sperm count and sperm concentration, while a significant correlation also was noted with sperm motility, percentage of live sperm, sperm morphology (normal and immature forms), and serum luteinizing hormone and testosterone levels. Sperm quantity had stronger correlations with testicular size than did sperm quality, although both were impaired in testes smaller than 14 ml. It is concluded that the size of the testis bears a direct correlation with testicular function and, thus, it can be helpful to assess rapidly andrological status during the initial physical examination.

Adult↗
PubMed1987

[Pharmacokinetics of high-dose cisplatin administration (relationship between pharmacokinetics and administration schedule)].

Three cases of urogenital malignancy were treated with 80-120/m2 of cisplatin by a 0.5-hour (rapid) or 4-hour (slow) infusion. Each patient received three courses of repeated chemotherapy. The kinetics of total platinum was measured up to 48 hours in the blood and urine. The blood peak concentrations were achieved 6.0 micrograms/ml by rapid infusion, 2.0 micrograms/ml by slow infusion. The time dependent urinary excretion rate against total administered dose was 40% in 60 min. by rapid infusion, 20% in 16 hours by slow infusion. The volume of distribution correlated with infusion time. Rapid infusion way of cisplatin could be better to treat the patient with bulky tumor mass or patients with uroepithelial cancer like CIS, because a higher blood and urine concentration can be obtained than by slow infusion.

Adolescent↗
PubMed1986

[Clinical experience of methylcobalamin (CH3-B12)/clomiphene citrate combined treatment in male infertility].

Infertile men (excluding azoospermia) were divided into three groups to test methylcobalamin (CH3-B12) + clomiphene citrate (Clomid) treatment. Group M: CH3-B12 (1,500 micrograms/day, daily for 8 to 60 weeks), Group C: Clomid (25 mg/day for 25 days followed by a 5-day rest period, for 8 to 48 weeks), and Group MC: CH3-B12 + Clomid (CH3-B12: 1,500 micrograms/day, daily and Clomid: 25 mg/day for 25 days followed by a 5-day rest period, for 12 to 24 weeks semen analysis was conducted before and after these administrations. Judging by our criteria, 60.0% (24/40) of the cases in Group M, 71.4%(25/35) in Group C, and 66.7% (8/12) in Group MC were improved. However, in patients whose sperm concentrations were over 10 X 10(6)/ml, 61.9% (13/21) of the cases in Group M, 69.2% (9/13) in Group C, and 80.0% (4/5) in Group MC were improved. Therefore, CH3-B12 + Clomid treatment was successful for patients whose sperm concentrations was over 10 X 10(6)/ml.

Adult↗
PubMed1985

[The effectiveness of chemotherapy and craniotomy for brain metastasis of non-seminomatous testicular tumor].

Four patients with non-seminomatous testicular tumor who already had brain metastasis were treated with combination chemotherapy. Three patients had received craniotomy in an effort to remove the metastatic lesion and intracranial hematoma. Two of them who were treated with PVB chemotherapy, which was effective against pulmonary and retroperitoneal metastasis but not against the brain metastatic lesions, died within 3 months; the other patient is receiving intense postcraniotomy chemotherapy using Cisplatin and large doses of Methotrexate administered with the Leucovorin rescue method which has shown a remarkable response against the brain metastasis of choriocarcinoma. The remaining patient has been receiving VAB VI protocol for 3 months. The metastatic lesion in the temporal lobe of his brain may consolidate through calcification, similar to the calcified change observed in the retroperitoneal lymph-node after chemotherapy. We discuss potential ways to induce improved therapeutic effects against brain metastasis of the non-seminomatous testicular tumor: It may be difficult to achieve an effective drug concentration level in the tissue immediately adjacent to the intracerebral tumor, because of the blood brain barrier. As induction therapy, a large dose of Cisplatinum (230 mg/body) or Methotrexate (10 g/body) was effective in attaining an effective drug concentration level in the tissue adjacent to tumor. Prior to the stem cell assay of the brain metastatic tumor, 1,100 mg Cisplatinum and 1,700 mg VP 16 were administered for treatment. The results of the stem cell assay in vitro showed a resistance to Cisplatinum and VP 16. Routine brain CT scanning is useful for detecting a metastatic lesion in its development. If detected, multidisciplinary chemotherapy should be performed.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1985

[Chemosensitivity testing using stem cell assay in urological and other malignancies].

We have attempted to grow several kinds of malignant tumors using human tumor stem cell assay. Formation of colonies in vitro was seen in 65 of 132 primary tumors (49%), including 25 of 41 (61%) uroepithelial cancers, 12 of 19 (63%) renal cancers, five of 12 (42%) testicular cancers, five of 21 (24%) gastrointestinal malignancies, five of 12 (42%) lung cancers, five of 11 (45%) hematopoietic malignancies and five of 16 (31%) other malignancies. Growth sufficient for in vitro chemosensitivity tests of CDDP developed from seven cases of uroepithelial cancer, three of them (43%) were sensitive to 2.5 micrograms X hour/ml of CDDP. The specimens from a metastatic testicular tumors that received several courses of PVB chemotherapy resulted in the resistance of the in vitro chemosensitivity test at a higher dosage of CDDP. Nine cases of renal cancer had sufficient growth for an in vitro chemosesitivity test of interferon. One of them was sensitive for alpha 2 type interferon. Three of seven cases were sensitive for alpha type of interferon. To predict clinical correlation, 19 patients were tested with the same drugs used in the in vitro chemosensitivity test. The predictability resulted in more than 60% of true positive, 91% of true negative and 86% of overall predictability.

Antineoplastic Agents↗
PubMed1984

[Clinical experience with methylcobalamin (CH3-B12) for male infertility].

CH3-B12 was administered daily (1,500 micrograms/day, for 4 to 24 weeks) to 26 infertile male patients who visited our clinic from January to December, 1982. It was not administered, however, to patients with azoospermia. Semen analysis was conducted from 8 weeks after the administration of CH3-B12. Sperm concentration increased in 10 cases (38.4%), total sperm counts increased in 14 cases (53.8%), sperm motility increased in 13 cases (50.0%) and total motile sperm count increased in 13 cases (50.0%). Semen volume, however, could not be evaluated due to wide variation. Serum LH, FSH and testosterone were unchanged. Judging by our criteria, 11 cases (42.3%) improved, 11 cases (42.3%) were unchanged and the remaining 4 cases (15.4%) had aggravated.

Adult↗